Genomic Health(NASDAQ:GHDX) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during After-Market on Feb 14, 2017. Based on the corporate Earnings and Guidance, many Investment Banking firms balance their portfolio to Sell and Buy Stocks based on their strategy of investing in stocks.Company reported revenue of $82.741M. Analysts estimated a revenue of $84.080M. The revenues were -1.59% below the estimates. Earnings per share were $0.04. The reported EPS was above estimates by 500%. Analysts had estimated an EPS of $-0.01.
In a different note, Deutsche Bank said it Initiates Coverage On Genomic Health, according to a research note issued on Jan 18, 2017. In the research note, the firm Announces the price-target to $31 per share. The shares have been rated ‘Hold’ by the firm.
Genomic Health (GHDX) made into the market gainers list on Wednesdays trading session with the shares advancing 0.31% or 0.09 points. Due to strong positive momentum, the stock ended at $28.89, which is also near the day’s high of $29. The stock began the session at $28.8 and the volume stood at 1,18,543 shares. The 52-week high of the shares is $33.96 and the 52 week low is $22. The company has a current market capitalization of $967 M and it has 3,34,79,260 shares in outstanding.
Several Insider Transactions has been reported to the SEC. On Jan 25, 2017, Steven Shak (Chief Scientific Officer) sold 5,000 shares at $27.28 per share price.Also, On Jan 12, 2017, G Bradley Cole (COO) sold 5,000 shares at $29.22 per share price.On Dec 6, 2016, Kimberly J Popovits (President and CEO) sold 5,000 shares at $30.02 per share price, according to the Form-4 filing with the securities and exchange commission.
Genomic Health Inc. is a healthcare company that provides actionable genomic information to personalize cancer treatment decisions. The Company offers its Oncotype DX tests as a clinical laboratory service where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score which it calls a Recurrence Score for invasive breast cancer and colon cancer a DCIS Score for ductal carcinoma in situ (DCIS) and a Genomic Prostate Score (GPS) for prostate cancer. The Company’s Oncotype DX platform utilizes quantitative genomic analysis known as reverse transcription polymerase chain reaction (RT-PCR) in standard tumor pathology specimens to provide tumor-specific information or the oncotype of a tumor. Its offerings also include Oncotype DX Breast Cancer Test Oncotype DX Colon Cancer Test and Oncotype DX Prostate Cancer Test.